专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

SG11201909955XA FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES 未知
公开(公告)号：SG11201909955XA
公开(公告)日：2019-11-28
申请号：SG11201909955X
申请日：2018-05-01
申请人： MERCK SHARP & DOHME
发明人： DESAI PREETI , SHI SHUAI , ANTOCHSHUK VALENTYN , BURLAGE RUBI , RAGHAVA SMITA
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28 , C07K16/46 , C07K19/00 , C12P21/08
摘要： INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 08 November 2018 (08.11.2018) WIPO I PCT omit VIII °nolo oloionmll VIII VIII oimIE (10) International Publication Number WO 2018/204374 Al (51) International Patent Classification: A61K 39/395 (2006.01) C07K 16/46 (2006.01) C07K 16/00 (2006.01) C07K 19/00 (2006.01) C07K 16/28 (2006.01) C12P 21/08 (2006.01) (21) International Application Number: PCT/US2018/030468 (22) International Filing Date: 01 May 2018 (01.05.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 62/500,330 02 May 2017 (02.05.2017) US (71) Applicant: MERCK SHARP & DOHME CORP. [US/US]; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (72) Inventors; and (71) Applicants (for US only): DESAI, Preeti, G. [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). SHI, Shuai [CN/US]; 6 Barberry Court, Whippa- ny, New Jersey 07981 (US). ANTOCHSHUK, Valentyn [US/US]; 2000 Galloping Hill Road, Kenilworth, New Jer- sey 07033 (US). BURLAGE, Rubi [US/US]; 2000 Gal- loping Hill Road, Kenilworth, New Jersey 07033 (US). RAGHAVA, Smita [IN/US]; 2000 Galloping Hill Road, Kenilworth, New Jersey 07033 (US). (74) Common Representative: MERCK SHARP & DOHME CORP.; 126 East Lincoln Avenue, Rahway, New Jersey 07065-0907 (US). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, = (54) Title: FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES Diffusion Interaction Parameter (K D ) Y 0.0 -- E —2.5- g —5.0- -7.5- 8 —10.0- c g o —15.0 L—arginine L histidine A Sodium chloride N O 40 I mM 70 I mM 100mM Concentration (mM) FIG.15 1-1 \" (57) : The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and C anti-LAG3 antibodies, and their use in treating various disorders. [Continued on next page] WO 2018/204374 Al MIDEDIMOMOIDEIRDERIHIMINIMIIHOHMEHOIMIE TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Declarations under Rule 4.17: as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(11)) as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii)) Published: with international search report (Art. 21(3)) before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h)) with sequence listing part of description (Rule 5.2(a))

2. 发明专利

CO2019012353A2 Formulaciones de anticuerpos anti-lag3 y coformulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1 未知
公开(公告)号：CO2019012353A2
公开(公告)日：2020-01-17
申请号：CO2019012353
申请日：2019-11-01
申请人： MERCK SHARP & DOHME
发明人： DESAI PREETI G , SHI SHUAI , ANTOCHSHUK VALENTYN , BURLAGE RUBI , RAGHAVA SMITA
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28 , C07K16/46 , C07K19/00 , C12P21/08
摘要： La presente invención proporciona formulaciones de anticuerpos anti-LAG3, y coformulaciones de anticuerpos anti-PD-1 y anticuerpos anti-LAG3, y su uso en el tratamiento de distintos trastornos.

3. 发明专利

CL2019003144A1 Formulaciones de anticuerpos anti-lag3 y co-formulaciones de anticuerpos anti-lag3 y anticuerpos anti-pd-1. 未知
公开(公告)号：CL2019003144A1
公开(公告)日：2020-05-08
申请号：CL2019003144
申请日：2019-10-30
申请人： MERCK SHARP & DOHME
发明人： DESAI PREETI G , SHI SHUAI , ANTOCHSHUK VALENTYN , BURLAGE RUBI , RAGHAVA SMITA
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28 , C07K16/46 , C07K19/00 , C12P21/08
摘要： La presente invención proporciona formulaciones de anticuerpos anti-LAG3, y coformulaciones de anticuerpos anti-PD-1 y anticuerpos anti-LAG3, y su uso en el tratamiento de distintos trastornos.

4. 发明专利

AU2018263868A1 Formulations of anti-LAG3 antibodies and co-formulations of anti-LAG3 antibodies and anti-PD-1 antibodies 未知
公开(公告)号：AU2018263868A1
公开(公告)日：2019-12-12
申请号：AU2018263868
申请日：2018-05-01
申请人： MERCK SHARP & DOHME
发明人： DESAI PREETI G , SHI SHUAI , ANTOCHSHUK VALENTYN , BURLAGE RUBI , RAGHAVA SMITA
IPC分类号： C07K19/00 , A61K39/395 , C07K16/00 , C07K16/28 , C07K16/46 , C12P21/08
摘要： The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.

5. 发明专利

CA3060581A1 FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND CO-FORMULATIONS OF ANTI-LAG3 ANTIBODIES AND ANTI-PD-1 ANTIBODIES 未知
公开(公告)号：CA3060581A1
公开(公告)日：2018-11-08
申请号：CA3060581
申请日：2018-05-01
申请人： MERCK SHARP & DOHME
发明人： DESAI PREETI G , SHI SHUAI , ANTOCHSHUK VALENTYN , BURLAGE RUBI , RAGHAVA SMITA
IPC分类号： A61K39/395 , C07K16/00 , C07K16/28 , C07K16/46 , C07K19/00 , C12P21/08
摘要： The present invention provides formulations of anti-LAG3 antibodies, and co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.

6. 发明公开

EP2919812A4 LIQUID FORMULATIONS FOR TNFR:FC FUSION PROTEINS 审中-公开
标题翻译：液体制剂TNFR：Fc融合蛋白
公开(公告)号：EP2919812A4
公开(公告)日：2016-05-18
申请号：EP13854963
申请日：2013-11-15
申请人： MERCK SHARP & DOHME
发明人： KASHI RAMESH S , PATEL SHONA P , MITTAL SARITA , BASARKAR ASHWIN , SHI SHUAI
IPC分类号： A61K39/395 , A61K38/17 , A61K47/18 , A61K47/26 , C07K14/715
CPC分类号： A61K47/26 , A61K38/1793 , A61K47/02 , A61K47/12 , A61K47/183 , A61K47/22 , C07K14/7151 , C07K2319/30
摘要： The invention provides stable liquid formulations for a recombinant biopharmaceutical protein comprising a soluble form of the human p75 TNF receptor fused to an Fe domain of a human immunoglobulin protein (TNFR:Fc). Typically, biopharmaceutical proteins such as monoclonal antibodies (mAbs) and immunoglobulin fusion proteins (e.g., immunoadhesion proteins) are produced by recombinant DNA technology in mammalian cell expression systems. In order to guarantee the reproducible clinical performance of a biopharmaceutical product, manufacturers have to deliver a product of consistent and reproducible quality.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式